Review

cdk9 inhibitor ldc000067 (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress cdk9 inhibitor ldc000067
GBP1 drives STAT3 activation and PD-L1 upregulation through <t>CDK9.</t>

Cdk9 Inhibitor Ldc000067, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk9 inhibitor ldc000067/product/MedChemExpress
Average 93 stars, based on 14 article reviews

cdk9 inhibitor ldc000067 - by Bioz Stars, 2026-03

93/100 stars

Images

1) Product Images from "GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape"

Article Title: GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape

Journal: Neoplasia (New York, N.Y.)

doi: 10.1016/j.neo.2025.101232

Figure Legend Snippet: GBP1 drives STAT3 activation and PD-L1 upregulation through CDK9.

Techniques Used: Activation Assay

Image Search Results

Journal: Neoplasia (New York, N.Y.)

Article Title: GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape

doi: 10.1016/j.neo.2025.101232

Figure Lengend Snippet: GBP1 drives STAT3 activation and PD-L1 upregulation through CDK9.

Article Snippet: The STAT3 inhibitor STAT3-IN-13 (HY-150603) and the CDK9 inhibitor LDC000067 (Synonyms: LDC067, HY-15878) were purchased from MedChemExpress (Monmouth Junction, USA). siRNAs were procured from RiboBio (Guangzhou, China).

Techniques: Activation Assay

Figure 1. Different CDK9 staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.

Journal: Oncology reports

Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

doi: 10.3892/or.2020.7746

Figure Lengend Snippet: Figure 1. Different CDK9 staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.

Article Snippet: The highly selective CDK9 inhibitor LDC000067 (abbreviated as LDC067) was purchased from Selleck Chemicals.

Techniques: Staining

Figure 3. CDK9 expression in endometrial cancer cell lines. (A) Expression levels of CDK9 in endometrial cancer cell lines (AN3CA, ARK‑2, HEC‑1A, HEC‑1B, lshikawa, RL95‑2 and SPAC1S) as determined by western blotting. (B) Relative expression of CDK9 and α‑tubulin in the endometrial cancer cell lines. CDK9, cyclin‑dependent kinase 9.

Journal: Oncology reports

Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

doi: 10.3892/or.2020.7746

Figure Lengend Snippet: Figure 3. CDK9 expression in endometrial cancer cell lines. (A) Expression levels of CDK9 in endometrial cancer cell lines (AN3CA, ARK‑2, HEC‑1A, HEC‑1B, lshikawa, RL95‑2 and SPAC1S) as determined by western blotting. (B) Relative expression of CDK9 and α‑tubulin in the endometrial cancer cell lines. CDK9, cyclin‑dependent kinase 9.

Article Snippet: The highly selective CDK9 inhibitor LDC000067 (abbreviated as LDC067) was purchased from Selleck Chemicals.

Techniques: Expressing, Western Blot

Figure 2. Higher expression of CDK9 is present in metastatic and recurrent endometrial cancer tissues compared with that found in the patient matched primary tumors and CDK9 is correlated with poor patient prognosis. (A) Distribution of CDK9 immunohistochemical staining scores among primary, metastatic, and recurrent endometrial cancer tissues. (B and C) Correlation between expression of CDK9 in the primary endometrial cancer tissues (Low, CDK9 staining ≤2+; High, CDK9 staining ≥3+) and PFS (B) or OS (C) in endometrial cancer patients by Kaplan‑Meier survival curve analysis. CDK9, cyclin‑dependent kinase 9; PFS, progression‑free survival; OS, overall survival.

Journal: Oncology reports

Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

doi: 10.3892/or.2020.7746

Figure Lengend Snippet: Figure 2. Higher expression of CDK9 is present in metastatic and recurrent endometrial cancer tissues compared with that found in the patient matched primary tumors and CDK9 is correlated with poor patient prognosis. (A) Distribution of CDK9 immunohistochemical staining scores among primary, metastatic, and recurrent endometrial cancer tissues. (B and C) Correlation between expression of CDK9 in the primary endometrial cancer tissues (Low, CDK9 staining ≤2+; High, CDK9 staining ≥3+) and PFS (B) or OS (C) in endometrial cancer patients by Kaplan‑Meier survival curve analysis. CDK9, cyclin‑dependent kinase 9; PFS, progression‑free survival; OS, overall survival.

Article Snippet: The highly selective CDK9 inhibitor LDC000067 (abbreviated as LDC067) was purchased from Selleck Chemicals.

Techniques: Expressing, Immunohistochemical staining, Staining

Figure 5. CDK9 inhibitor reduces endometrial cancer cell proliferation by suppressing transcription elongation and inducing apoptosis in endometrial cancer cells. (A and B) Relative cell viability of AN3CA and SPAC1S cells after exposure to different concentrations of the CDK9 inhibitor LDC067 for 5 days. **P<0.01 compared with the lowest concentration group (1x10‑3 µM). (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after treatment with LDC067 in cells by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator; PARP, poly(ADP‑ribose) polymerase.

Journal: Oncology reports

Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

doi: 10.3892/or.2020.7746

Figure Lengend Snippet: Figure 5. CDK9 inhibitor reduces endometrial cancer cell proliferation by suppressing transcription elongation and inducing apoptosis in endometrial cancer cells. (A and B) Relative cell viability of AN3CA and SPAC1S cells after exposure to different concentrations of the CDK9 inhibitor LDC067 for 5 days. **P<0.01 compared with the lowest concentration group (1x10‑3 µM). (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after treatment with LDC067 in cells by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator; PARP, poly(ADP‑ribose) polymerase.

Article Snippet: The highly selective CDK9 inhibitor LDC000067 (abbreviated as LDC067) was purchased from Selleck Chemicals.

Techniques: Concentration Assay, Expressing, Western Blot

Figure 4. CDK9 knockdown by siRNA transfection suppresses endometrial cancer cell proliferation. (A and B) MTT assay revealed significant dose‑dependent inhibition of cell proliferation after CDK9 siRNA treatment. **P<0.01 compared with the cell only control group. (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after transfection of CDK9 siRNA and nonspecific siRNA (NC siRNA) in AN3CA and SPAC1S cell lines by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator.

Journal: Oncology reports

Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

doi: 10.3892/or.2020.7746

Figure Lengend Snippet: Figure 4. CDK9 knockdown by siRNA transfection suppresses endometrial cancer cell proliferation. (A and B) MTT assay revealed significant dose‑dependent inhibition of cell proliferation after CDK9 siRNA treatment. **P<0.01 compared with the cell only control group. (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after transfection of CDK9 siRNA and nonspecific siRNA (NC siRNA) in AN3CA and SPAC1S cell lines by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator.

Article Snippet: The highly selective CDK9 inhibitor LDC000067 (abbreviated as LDC067) was purchased from Selleck Chemicals.

Techniques: Knockdown, Transfection, MTT Assay, Inhibition, Control, Expressing, Western Blot

Figure 7. Inhibition of CDK9 reduces endometrial cancer cell migration. (A and B) Representative images of AN3CA and SPAC1S cell migration after CDK9 inhibitor LDC067 treatment for 0, 24, and 48 h. (C and D) Quantification of cell migration distance of AN3CA and SPAC1S cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

Journal: Oncology reports

Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

doi: 10.3892/or.2020.7746

Figure Lengend Snippet: Figure 7. Inhibition of CDK9 reduces endometrial cancer cell migration. (A and B) Representative images of AN3CA and SPAC1S cell migration after CDK9 inhibitor LDC067 treatment for 0, 24, and 48 h. (C and D) Quantification of cell migration distance of AN3CA and SPAC1S cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

Article Snippet: The highly selective CDK9 inhibitor LDC000067 (abbreviated as LDC067) was purchased from Selleck Chemicals.

Techniques: Inhibition, Migration

Figure 6. Inhibition of CDK9 suppresses endometrial cancer cell colony formation. (A) Representative images of endometrial cancer cell colony formation after incubation with different concentrations of LDC067 (0, 2.5, 5.0, and 10 µM) for 14 days. (B and C) Quantification of clonogenicity formation of AN3CA (B) and SPAC1S (C) cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

Journal: Oncology reports

Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

doi: 10.3892/or.2020.7746

Figure Lengend Snippet: Figure 6. Inhibition of CDK9 suppresses endometrial cancer cell colony formation. (A) Representative images of endometrial cancer cell colony formation after incubation with different concentrations of LDC067 (0, 2.5, 5.0, and 10 µM) for 14 days. (B and C) Quantification of clonogenicity formation of AN3CA (B) and SPAC1S (C) cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

Article Snippet: The highly selective CDK9 inhibitor LDC000067 (abbreviated as LDC067) was purchased from Selleck Chemicals.

Techniques: Inhibition, Incubation

Correlations between CDK9 expression and clinicopathological features

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

doi: 10.7150/jca.35426

Figure Lengend Snippet: Correlations between CDK9 expression and clinicopathological features

Article Snippet: The highly selective inhibitor of CDK9 (LDC000067) was purchased from Selleck Chemicals (Houston, TX).

Techniques: Expressing

Correlation between CDK9 expression and clinicopathological outcomes for chordoma patients. (A) Representative images of different immunohistochemical stain intensities of CDK9. On the basis of the percentage of cells with positive nuclear staining, CDK9 staining patterns were categorized into 6 groups: 0, no nuclear staining; 1+: <10% of positive cells; 2+, 10%-25% of positive cells; 3+, 26%-50% of positive cells; 4+, 51%-75% of positive cells; 5+, >75% of positive cells. Original magnification 200×. (B) Pie chart representing relative frequency of different CDK9 staining patterns in chordoma tissue microarrays. (C) Kaplan-Meier curves depicting overall survival rates in the two groups of chordoma patients by CDK9 staining pattern. Low expression (number=24) mean OS = 78.4 months, high expression (number=31) mean OS = 50.2 months, p=0.0026. (D) Kaplan-Meier curves depicting progression-free survival rates in the two groups of chordoma patients by CDK9 staining pattern. Low expression (number=24) mean PFS= 57.5 months, high expression (number=31) mean PFS= 33.0 months, p=0.0035 (E) Levels of CDK9 expression in chordoma patients with primary chordoma (number=20, mean score=2.25), patients who developed recurrence (number=32, mean score=3.29) or metastasis (number=8, mean score=2.87).

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

doi: 10.7150/jca.35426

Figure Lengend Snippet: Correlation between CDK9 expression and clinicopathological outcomes for chordoma patients. (A) Representative images of different immunohistochemical stain intensities of CDK9. On the basis of the percentage of cells with positive nuclear staining, CDK9 staining patterns were categorized into 6 groups: 0, no nuclear staining; 1+: <10% of positive cells; 2+, 10%-25% of positive cells; 3+, 26%-50% of positive cells; 4+, 51%-75% of positive cells; 5+, >75% of positive cells. Original magnification 200×. (B) Pie chart representing relative frequency of different CDK9 staining patterns in chordoma tissue microarrays. (C) Kaplan-Meier curves depicting overall survival rates in the two groups of chordoma patients by CDK9 staining pattern. Low expression (number=24) mean OS = 78.4 months, high expression (number=31) mean OS = 50.2 months, p=0.0026. (D) Kaplan-Meier curves depicting progression-free survival rates in the two groups of chordoma patients by CDK9 staining pattern. Low expression (number=24) mean PFS= 57.5 months, high expression (number=31) mean PFS= 33.0 months, p=0.0035 (E) Levels of CDK9 expression in chordoma patients with primary chordoma (number=20, mean score=2.25), patients who developed recurrence (number=32, mean score=3.29) or metastasis (number=8, mean score=2.87).

Article Snippet: The highly selective inhibitor of CDK9 (LDC000067) was purchased from Selleck Chemicals (Houston, TX).

Techniques: Expressing, Immunohistochemical staining, Staining

The clinical parameters of chordoma tissue microarray

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

doi: 10.7150/jca.35426

Figure Lengend Snippet: The clinical parameters of chordoma tissue microarray

Article Snippet: The highly selective inhibitor of CDK9 (LDC000067) was purchased from Selleck Chemicals (Houston, TX).

Techniques: Biomarker Discovery, Expressing

CDK9 expression in chordoma cell lines and tissues. (A) CDK9 expression in chordoma cell lines. (B and C) CDK9 expression in chordoma tissues. There are 2 isoforms of the CDK9 protein: the 42 KD CDK9 isoform and the 55 KD isoform. The smaller 42 KD isoform was the first identified isoform. Expression of CDK9 (55KD band) was normalized to α-Tubulin. (D) Cellular localization of CDK9 in UCH2 and CH22 cells was assessed by immunofluorescence with antibodies to CDK9 and actin.

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

doi: 10.7150/jca.35426

Figure Lengend Snippet: CDK9 expression in chordoma cell lines and tissues. (A) CDK9 expression in chordoma cell lines. (B and C) CDK9 expression in chordoma tissues. There are 2 isoforms of the CDK9 protein: the 42 KD CDK9 isoform and the 55 KD isoform. The smaller 42 KD isoform was the first identified isoform. Expression of CDK9 (55KD band) was normalized to α-Tubulin. (D) Cellular localization of CDK9 in UCH2 and CH22 cells was assessed by immunofluorescence with antibodies to CDK9 and actin.

Article Snippet: The highly selective inhibitor of CDK9 (LDC000067) was purchased from Selleck Chemicals (Houston, TX).

Techniques: Expressing, Immunofluorescence

Effect of CDK9 inhibition by siRNA on chordoma cell lines. (A and B) After transfected with increasing concentrations of CDK9 specific siRNA or nonspecific siRNA for 3 days, cell viability was determined by MTT assay after siRNA transfection in both UCH2 and CH22 cells. *p<0.05. (C and D) The morphology of UCH2 and CH22 cell lines changed after 3 days of siRNA transfection. α-Tubulin was used as a loading control. (E and F) The proteins of CDK9 and downstream proteins p-RNA II ser2 and Mcl-1 in cells were examined by Western blot after 3 days of siRNA transfection.

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

doi: 10.7150/jca.35426

Figure Lengend Snippet: Effect of CDK9 inhibition by siRNA on chordoma cell lines. (A and B) After transfected with increasing concentrations of CDK9 specific siRNA or nonspecific siRNA for 3 days, cell viability was determined by MTT assay after siRNA transfection in both UCH2 and CH22 cells. *p<0.05. (C and D) The morphology of UCH2 and CH22 cell lines changed after 3 days of siRNA transfection. α-Tubulin was used as a loading control. (E and F) The proteins of CDK9 and downstream proteins p-RNA II ser2 and Mcl-1 in cells were examined by Western blot after 3 days of siRNA transfection.

Article Snippet: The highly selective inhibitor of CDK9 (LDC000067) was purchased from Selleck Chemicals (Houston, TX).

Techniques: Inhibition, Transfection, MTT Assay, Control, Western Blot

Effect of CDK9 inhibitor treatment on chordoma cell lines. (A and B) After exposure to increasing concentrations of CDK9 inhibitor for 120 h, cell viability was decreased in a dose-dependent manner in both UCH2 and CH22 cells, with the IC50 values for LDC000067 at 3.22 µM and 4.47 µM, respectively. (C) After incubation of UCH2 and CH22 cell lines with 1.25 µM, 2.5µM, 5.0µM, and 10.0 µM LDC000067 for 48 h, they showed a strong decrease of p-RNA II ser2 and Mcl-1 expression with increasing LDC000067 concentration. α-Tubulin was used as a loading control.

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

doi: 10.7150/jca.35426

Figure Lengend Snippet: Effect of CDK9 inhibitor treatment on chordoma cell lines. (A and B) After exposure to increasing concentrations of CDK9 inhibitor for 120 h, cell viability was decreased in a dose-dependent manner in both UCH2 and CH22 cells, with the IC50 values for LDC000067 at 3.22 µM and 4.47 µM, respectively. (C) After incubation of UCH2 and CH22 cell lines with 1.25 µM, 2.5µM, 5.0µM, and 10.0 µM LDC000067 for 48 h, they showed a strong decrease of p-RNA II ser2 and Mcl-1 expression with increasing LDC000067 concentration. α-Tubulin was used as a loading control.

Article Snippet: The highly selective inhibitor of CDK9 (LDC000067) was purchased from Selleck Chemicals (Houston, TX).

Techniques: Incubation, Expressing, Concentration Assay, Control

Effects of CDK9 inhibition on clonogenic assay and 3D culture. (A and B) Representative results of colony formation of chordoma cell lines treated with CDK9 inhibitor. (C) Assessed spheroid formation of chordoma cell lines treated with CDK9 inhibitor in 3D cell culture.

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

doi: 10.7150/jca.35426

Figure Lengend Snippet: Effects of CDK9 inhibition on clonogenic assay and 3D culture. (A and B) Representative results of colony formation of chordoma cell lines treated with CDK9 inhibitor. (C) Assessed spheroid formation of chordoma cell lines treated with CDK9 inhibitor in 3D cell culture.

Article Snippet: The highly selective inhibitor of CDK9 (LDC000067) was purchased from Selleck Chemicals (Houston, TX).

Techniques: Inhibition, Clonogenic Assay, Cell Culture

Review

Structured Review

Images

1) Product Images from "GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape"

Similar Products

Image Search Results